Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof
Disclosed is a liver specific delivery (LSD)-based entecavir antiviral prodrug, i.e., a nucleoside cyclic phosphate compound, and the application thereof. Specifically, disclosed are a compound as represented by formula (I) and isomers, pharmaceutically acceptable salts, hydrates, and solvates of the compound, and a corresponding pharmaceutical composition. Also disclosed is the application of the compound of the present invention, used separately or used in combination with other antiviral drugs, against viruses, especially the application against hepatitis B virus (HBV).
1. A compound of formula (I), or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof:
wherein
R 2 is Cl and R 3 is F; or R 2 is Cl and R 3 is Cl; or R 2 is F and R 3 is Cl; and
m is O.
2. The compound according to claim 1 , or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein a salt of the compound of formula (I) is a pharmaceutically acceptable salt formed from the compound of formula (I) with an inorganic acid or an organic acid, or formed from the compound of formula (I) with a base, and the compound of formula (I) or the salt thereof is amorphous or crystalline.
3. A pharmaceutical composition, comprising a therapeutically effective amount of the compound, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof of claim 1 and a pharmaceutically acceptable adjuvant, diluent, or carrier.
4. A method for treating hepatitis B virus infection, in a subject, comprising:
administering to the subject an effective amount of the compound, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof of claim 1 .
5. A method according for preparing the compound of claim 1 , wherein the compound of formula (I) is prepared through the step of:
(i-b) removing TBS from a compound of formula (Ia) in an inert solvent to form the compound of formula (I),
wherein each group in the formulas is defined in the same manner as in claim 1 ;
wherein the compound of formula (Ia) is prepared through the step of:
(i-c) subjecting a compound of formula (Ic) and PA3001-3 to a substitution reaction in an inert solvent to obtain the compound of formula (Ia).